BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 20197284)

  • 1. Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study.
    Haag-Weber M; Krämer R; Haake R; Islam MS; Prischl F; Haug U; Nabut JL; Deppisch R;
    Nephrol Dial Transplant; 2010 Jul; 25(7):2288-96. PubMed ID: 20197284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial.
    Szeto CC; Chow KM; Lam CW; Leung CB; Kwan BC; Chung KY; Law MC; Li PK
    Nephrol Dial Transplant; 2007 Feb; 22(2):552-9. PubMed ID: 17005526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A combination of biocompatible peritoneal dialysis solutions and residual renal function, peritoneal transport, and inflammation markers: a randomized clinical trial.
    Lui SL; Yung S; Yim A; Wong KM; Tong KL; Wong KS; Li CS; Au TC; Lo WK; Ho YW; Ng F; Tang C; Chan TM
    Am J Kidney Dis; 2012 Dec; 60(6):966-75. PubMed ID: 22835900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
    Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
    Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study.
    Kim S; Oh J; Kim S; Chung W; Ahn C; Kim SG; Oh KH
    Nephrol Dial Transplant; 2009 Sep; 24(9):2899-908. PubMed ID: 19258384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of neutral pH and low-glucose degradation product-containing peritoneal dialysis solution on residual renal function in peritoneal dialysis patients: a meta-analysis.
    Wang J; Zhu N; Yuan W
    Nephron; 2015; 129(3):155-63. PubMed ID: 25765060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Better preservation of residual renal function in peritoneal dialysis patients treated with a low-protein diet supplemented with keto acids: a prospective, randomized trial.
    Jiang N; Qian J; Sun W; Lin A; Cao L; Wang Q; Ni Z; Wan Y; Linholm B; Axelsson J; Yao Q
    Nephrol Dial Transplant; 2009 Aug; 24(8):2551-8. PubMed ID: 19258386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of iodinated contrast agents on residual renal function in PD patients.
    Moranne O; Willoteaux S; Pagniez D; Dequiedt P; Boulanger E
    Nephrol Dial Transplant; 2006 Apr; 21(4):1040-5. PubMed ID: 16352623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study.
    Fusshoeller A; Plail M; Grabensee B; Plum J
    Nephrol Dial Transplant; 2004 Aug; 19(8):2101-6. PubMed ID: 15213322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of neutral pH and low-glucose degradation product-containing peritoneal dialysis fluid on systemic markers of inflammation and endothelial dysfunction: a randomized controlled 1-year follow-up study.
    Park SH; Do JY; Kim YH; Lee HY; Kim BS; Shin SK; Kim HC; Chang YK; Yang JO; Chung HC; Kim CD; Lee WK; Kim JY; Kim YL
    Nephrol Dial Transplant; 2012 Mar; 27(3):1191-9. PubMed ID: 21862454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of furosemide in patients on peritoneal dialysis.
    Flinn A; Ledger S; Blake P
    CANNT J; 2006; 16(3):40-4. PubMed ID: 17061696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline peritoneal solute transport rate is not associated with markers of systemic inflammation or comorbidity in incident Korean peritoneal dialysis patients.
    Oh KH; Moon JY; Oh J; Kim SG; Hwang YH; Kim S; Lee JS; Ahn C
    Nephrol Dial Transplant; 2008 Jul; 23(7):2356-64. PubMed ID: 18178604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time profiles of peritoneal and renal clearances of different uremic solutes in incident peritoneal dialysis patients.
    Bammens B; Evenepoel P; Verbeke K; Vanrenterghem Y
    Am J Kidney Dis; 2005 Sep; 46(3):512-9. PubMed ID: 16129214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane.
    Williams JD; Topley N; Craig KJ; Mackenzie RK; Pischetsrieder M; Lage C; Passlick-Deetjen J;
    Kidney Int; 2004 Jul; 66(1):408-18. PubMed ID: 15200450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of healthy start peritoneal dialysis on the evolution of residual renal function and nutrition parameters.
    Van Biesen W; Dequidt C; Vanholder R; Lameire N
    Adv Perit Dial; 2002; 18():44-8. PubMed ID: 12402585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of angiotensin converting enzyme inhibitors on potassium homeostasis in dialysis patients with and without residual renal function.
    Garthwaite E; Bhandari S
    Artif Organs; 2009 Aug; 33(8):641-7. PubMed ID: 19624582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative study of enalapril vs. losartan on residual renal function preservation in automated peritoneal dialysis. A randomized controlled study.
    Reyes-Marín FA; Calzada C; Ballesteros A; Amato D
    Rev Invest Clin; 2012; 64(4):315-21. PubMed ID: 23227581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced systemic advanced glycation end products in children receiving peritoneal dialysis with low glucose degradation product content.
    Schmitt CP; von Heyl D; Rieger S; Arbeiter K; Bonzel KE; Fischbach M; Misselwitz J; Pieper AK; Schaefer F;
    Nephrol Dial Transplant; 2007 Jul; 22(7):2038-44. PubMed ID: 17420168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between residual renal function, inflammation, and anemia in peritoneal dialysis.
    Pérez-Flores I; Coronel F; Cigarrán S; Herrero JA; Calvo N
    Adv Perit Dial; 2007; 23():140-3. PubMed ID: 17886621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Trio Trial - A Randomized Controlled Clinical Trial Evaluating the Effect of a Biocompatible Peritoneal Dialysis Solution on Residual Renal Function.
    Sikaneta T; Wu G; Abdolell M; Ng A; Mahdavi S; Svendrovski A; Tu T; Mercer T; Tong M; Oreopoulos D; Tam P
    Perit Dial Int; 2016 9-10; 36(5):526-32. PubMed ID: 27282852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.